Table 2.

Time on treatment and overall survival among overall study population of patients with mNSCLC and PD-L1 expression ≥50% (n=505) that initiated 1L pembrolizumab monotherapy (Kaplan-Meier estimate).

Time on treatment variables	N = 505
Discontinuations	378
Median rwToT (95% CI), months	7.0 (6.0-8.4)
On-treatment rates, % (95% CI)
6 months	54.6 (50.2-59.3)
12 months	34.2 (30.0-39.1)
18 months	23.7 (19.9-28.3)
24 months	16.6 (13.2-20.9)
30 months	13.0 (9.9-17.0)
36 months	9.8 (6.9-13.7)
Overall survival variables	N = 505
Deaths	246
Median OS (95% CI), months	24.5 (20.1-29.3)
Survival rates, % (95% CI)
6 months	80.5 (76.9-84.1)
12 months	66.8 (62.5-71.4)
18 months	57.5 (52.9-62.5)
24 months	50.6 (45.9-55.9)
30 months	43.5 (38.7-49.0)
36 months	39.4 (34.5-45.0)

CI, confidence interval; OS, overall survival; rwToT, real-world time on treatment.